Vedolizumab is a monoclonal antibody used for treating moderate to severe active ulcerative colitis (UC) and Crohn’s disease (CD) in adults.
Vedolizumab injection is used for treating adult patients with moderate to severe active ulcerative colitis and Crohn’s disease who have had an inadequate response or no response or who were intolerant to other treatment methods such as with drugs that causes tumor necrosis factor (TNF) block (such as Infliximab or Etanercept) or an immunomodulatory (azathioprine, methotrexate or cyclosporine) or a corticosteroid.
It helps for inducing and maintaining clinical response and clinical remission, improving the endoscopic appearance of the mucosa and achieving corticosteroid-free remission.
Vedolizumab should not be used:
• If there is an allergy to vedolizumab
• In patients with severe infections.
Vedolizumab is available as injection containing 300mg of drug
For adult UC and CD, it is given as 300 mg intravenous infusion over 30 minutes at zero, two and six weeks, thereafter for every eight weeks.
• Vedolizumab should be discontinued in patients who do not show therapeutic benefit by Week 14.
• It should be reconstituted and diluted with sterile water for injection prior to the administration. It should be reconstituted and prepared by a trained healthcare professional using aseptic technique.
• Injection should be given within four hours of reconstitution and dilution.
• Visually inspect the reconstituted vedolizumab injection for any particulate matter and discoloration prior to administration. Injection should be clear or opalescent, colorless to light brownish yellow and free of visible particulates.
• Discard any remaining portion of the injection.
• Do not add other medicines to the prepared infusion solution or intravenous infusion set. Injection should be used as soon as possible after reconstitution and dilution.
• Discontinue in case of an allergic reaction during infusion.
• Caution is needed in case of using vedolizumab in patients with progressive multifocal leukoencephalopathy (PML).
• Caution is needed in case of using vedolizumab in patients with liver damage.
• Caution is exercised in case of using vedolizumab in patients who are going to take live vaccines. Hence, patients are advised to bring their immunization card up to date.
Nervous system: Headache
Respiratory: Inflammation of Nose and pharynx (Nasopharyngitis), upper respiratory tract infection, fatigue, cough, bronchitis, influenza, sinusitis, oropharyngeal pain
Others: Back pain , pain in limbs(legs)
Vedolizumab should be used during pregnancy only if the benefits to the mother are more than the risk to the unborn child.
Caution is needed when administering vedolizumab to breastfeeding women.
Vedolizumab may interact with natalizumab, live vaccines, and other immunomodulators
Refrigerate vedolizumab vials at 2° to 8°C (36º to 46ºF).
Subscribe to our Free Newsletters!